Norges Bank’s Cyclerion Therapeutics CYCN Stock Holding History

Norges Bank’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-623	Closed	-$34K	–	2059
2019 Q4	$34K	Hold	623	–	–	﹤0.01%	2074
2019 Q3	$151K	Hold	623	–	–	﹤0.01%	2083
2019 Q2	$142K	Buy	+623	New	+$176K	﹤0.01%	2084

Other funds holding CYCN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Norges Bank's CYCN Position: Q1 2020 in Review

Norges Bank sold out of Cyclerion Therapeutics (CYCN) in Q1 2020, closing a stake of 623 shares — an estimated $34K sold.

Norges Bank first reported a position in CYCN in Q2 2019 and held it in 3 quarters. The position peaked at $151K in Q3 2019. 80 funds tracked by Wall St. Rank hold CYCN as of Q1 2020.

Norges Bank reported no remaining Cyclerion Therapeutics position as of Q1 2020 after selling out during the quarter.
Norges Bank sold 623 Cyclerion Therapeutics shares in Q1 2020, an estimated $34K.
Norges Bank first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 3 quarters.
Norges Bank's Cyclerion Therapeutics position peaked at $151K in Q3 2019.
80 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2020.

Based on Norges Bank's 13F filing for Q1 2020, filed 8 May 2020.